FibroGen Adrift After Yet Another Pamrevlumab Failure
The asset appears to have a similar future in Duchenne muscular dystrophy as it has in idiopathic pulmonary fibrosis – to wit, none.
The asset appears to have a similar future in Duchenne muscular dystrophy as it has in idiopathic pulmonary fibrosis – to wit, none.